Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies

PLoS Neglected Tropical Diseases

Volumn 6, Issue 11, 2012, Pages

  Caljon, Guy ^a,b,c   Stijlemans, Benoît ^b,c   Saerens, Dirk ^b,c   van den Abbeele, Jan ^a   Muyldermans, Serge ^b,c   Magez, Stefan ^b,c   de Baetselier, Patrick ^b,c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NANOBODY; UNCLASSIFIED DRUG; VARIANT SURFACE GLYCOPROTEIN;

ANTIBODY AFFINITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING; EPITOPE MAPPING; FLAGELLUM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; NONHUMAN; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; MICE; MICE, INBRED C57BL; MICROBIAL VIABILITY; SINGLE-DOMAIN ANTIBODIES; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84870731528     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001902     Document Type: Article

References (35)

1. Beschin A, Brys L, Magez S, Radwanska M, De Baetselier P, (1998) Trypanosoma brucei infection elicits nitric oxide-dependent and nitric oxide-independent suppressive mechanisms. J Leukoc Biol 63: 429-439.
2. Darji A, Beschin A, Sileghem M, Heremans H, Brys L, et al. (1996) In vitro simulation of immunosuppression caused by Trypanosoma brucei: active involvement of gamma interferon and tumor necrosis factor in the pathway of suppression. Infect Immun 64: 1937-1943.
3. Radwanska M, Guirnalda P, De Trez C, Ryffel B, Black S, et al. (2008) Trypanosomiasis-induced B cell apoptosis results in loss of protective anti-parasite antibody responses and abolishment of vaccine-induced memory responses. PLoS Pathog 4: e1000078.
4. Bockstal V, Guirnalda P, Caljon G, Goenka R, Telfer JC, et al. (2011) T. brucei infection reduces B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through transitional B-cell apoptosis. PLoS Pathog 7: e1002089.
5. Donelson JE, (2003) Antigenic variation and the African trypanosome genome. Acta Trop 85: 391-404.
6. Pays E, Vanhamme L, Perez-Morga D, (2004) Antigenic variation in Trypanosoma brucei: facts, challenges and mysteries. Curr Opin Microbiol 7: 369-374.
7. Vanhamme L, Lecordier L, Pays E, (2001) Control and function of the bloodstream variant surface glycoprotein expression sites in Trypanosoma brucei. Int J Parasitol 31: 523-531.
8. Barry JD, McCulloch R, (2001) Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite. Adv Parasitol 49: 1-70.
9. Auffret CA, Turner MJ, (1981) Variant specific antigens of Trypanosoma brucei exist in solution as glycoprotein dimers. Biochem J 193: 647-650.
10. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
11. Nguyen VK, Desmyter A, Muyldermans S, (2001) Functional heavy-chain antibodies in Camelidae. Adv Immunol 79: 261-296.
12. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, et al. (1998) Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 17: 3512-3520.
13. Engstler M, Thilo L, Weise F, Grünfelder CG, Schwarz H, et al. (2004) Kinetics of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in Trypanosoma brucei. J Cell Sci 117: 1105-1115.
14. Balber AE, Bangs JD, Jones SM, Proia RL, (1979) Inactivation or elimination of potentially trypanolytic, complement-activating immune complexes by pathogenic trypanosomes. Infect Immun 24: 617-627.
15. O'Beirne C, Lowry CM, Voorheis HP, (1998) Both IgM and IgG anti-VSG antibodies initiate a cycle of aggregation-disaggregation of bloodstream forms of Trypanosoma brucei without damage to the parasite. Mol Biochem Parasitol 91: 165-193.
16. Stijlemans B, Caljon G, Natesan SK, Saerens D, Conrath K, et al. (2011) High affinity nanobodies against the Trypanosoma brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog 7: e1002072.
17. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S, (1997) Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol 34: 1121-1131.
18. Conrath K, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, et al. (2005) Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol 350: 112-125.
19. Cross GA, (1975) Identification, purification and properties of clone-specific glycoprotein antigens constituting the surface coat of Trypanosoma brucei. Parasitol 71: 393-417.
20. Lanham SM, Godfrey DG, (1970) Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp Parasitol 28: 521-534.
21. Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, et al. (2004) Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem 279: 51965-51972.
22. Saerens D, Stijlemans B, Baral TN, Nguyen Thi GT, Wernery U, et al. (2008) Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J Immunol Methods 329: 138-150.
23. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S, (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS lett 414: 521-526.
24. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, et al. (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279: 1256-1261.
25. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, et al. (2001) Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother 45: 2807-2812.
26. Allen CL, Goulding D, Field MC, (2003) Clathrin-mediated endocytosis is essential in Trypanosoma brucei. EMBO J 22: 4991-5002.
27. Garcia-Salcedo JA, Perez-Morga D, Gijon P, Dilbeck V, Pays E, et al. (2004) A differential role for actin during the life cycle of Trypanosoma brucei. EMBO J 23: 780-789.
28. Hall BS, Smith E, Langer W, Jacobs LA, Goulding D, et al. (2005) Developmental variation in Rab11-dependent trafficking in Trypanosoma brucei. Eukaryot Cell 4: 971-980.
29. Spitznagel D, O'Rourke JF, Leddy N, Hanrahan O, Nolan DP, (2010) Identification and characterization of an unusual class I myosin involved in vesicle traffic in Trypanosoma brucei. PLoS One 5: e12282.
30. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
31. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, et al. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177: 362-371.
32. Zamze SE, Ashford DA, Wooten EW, Rademacher TW, Dwek RA, (1991) Structural characterization of the asparagine-linked oligosaccharides from Trypanosoma brucei type II and type III variant surface glycoproteins. J Biol Chem 266: 20244-20261.
33. Leal S, Acosta-Serrano A, Morris J, Cross GA, (2004) Transposon mutagenesis of Trypanosoma brucei identifies glycosylation mutants resistant to concanavalin A. J Biol Chem 279: 28979-28988.
34. Pearson TW, Beecroft RP, Welburn SC, Ruepp S, Roditi I, et al. (2000) The major cell surface glycoprotein procyclin is a receptor for induction of a novel form of cell death in African trypanosomes in vitro. Mol Biochem Parasitol 111: 333-349.
35. De Vooght L, Caljon G, Stijlemans B, De Baetselier P, Coosemans M, et al. (2012) Expression and extracellular release of a functional anti-trypanosome Nanobody(R) in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microb Cell Fact 11: 23.